Latest news for PhotoCure (OTC:PHCUF) Stock

PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products specialty pharmaceutical companies. Its technology platform is focused on the field of photodynamic diagnosis and treatment of cancer. It has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, BeNeLux, Italy, Other European countries, and the United States.

PhotoCure ASA

Photocure ASA reports Q3 results

Photocure ASA reports Q4 results

Photocure ASA reports Q1 results

Photocure ASA (PHCUF) has released an update. Photocure ASA has launched a new initiative to expand access to blue light cystoscopy for bladder can...

Photocure ASA Enhances U.S. Bladder Cancer Care Access

Photocure ASA (PHCUF) has released an update. Photocure ASA collaborates with Richard Wolf GmbH to develop and globally commercialize a cutting-edg...

Photocure ASA Unveils Advanced Bladder Cancer Scope

Photocure ASA (PHCUF) has released an update. Photocure ASA reported Hexvix/Cysview revenues of NOK 122.4 million in Q2 2024, marking a 6% increase...

Photocure ASA Reports Growth and Optimistic Outlook

Photocure ASA reports Q2 results

Photocure ASA (PHCUF) has released an update. Photocure ASA has announced that its partner, Asieris Pharmaceuticals, will present Phase III clinica...

Photocure Announces Cevira's Successful Phase III Results

PHCUF

Press Releases

European Association of Urology (EAU) 2024 congress features new data on modern technology use in bladder cancer care

Earnings

Small Cap

Photocure ASA: Annual Report 2023

Photocure ASA - Notice of the Annual General Meeting 23 May 2024

Bladder Cancer: Long-Term Benefits of Blue Light Cystoscopy and Enhanced Detection with HD Technology Unveiled at AUA 2024

Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Cevira in China

Photocure ASA: Results for the first quarter of 2024

Photocure ASA - Annual general meeting held

Photocure Announces Mobile BLC Tower Initiative to Expand Access to Cysview in the U.S.

Photocure and Richard Wolf Enter into Agreement to Develop a High-Definition Flexible Blue Light Cystoscope for Global Commercialization

Photocure ASA: Results for the second quarter of 2024

PhotoCure

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

PhotoCure

News

Latest news for PhotoCure (OTC:PHCUF) Stock